Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686165 · ClinicalTrials.gov registry record · Phase 2
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01686165 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 5 participants.
The verdict
NCT01686165, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study looks at what effects (good and bad) a drug called PXD-101 (belinostat) in combination with the radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) has on patients with relapsed aggressive (high-risk) non-Hodgkin lymphoma. Studies in the laboratory suggest that drugs such as PXD101 can act upon specific cancer cell processes to cause either death of the cancer cells or prevention of their growth. In human studies with a small number of patients with this lymphoma, PXD-101 has shown the ability to shrink and slow tumor growth. When Zevalin is delivered directly to the tumor, the lymphoma cells are destroyed and this may result in the disappearance of the tumor (remission)
Interventions
- BIOLOGICAL rituximab
- RADIATION yttrium Y 90 ibritumomab tiuxetan
- DRUG belinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-08-31 |
| Est. Completion | 2017-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686165
The ClinicalTrials.gov registry entry for NCT01686165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rituximab is the first listed.
NCT01686165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01686165 about?
NCT01686165 is a clinical study titled "Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL". This study looks at what effects (good and bad) a drug called PXD-101 (belinostat) in combination with the radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) has on patients with relapsed aggressive (high-risk) non-Hodgkin lymphoma. Studies in the laboratory suggest that drugs such as PXD1...
What is the current status of trial NCT01686165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-08-31. Estimated completion is 2017-11-09.
What interventions are being tested in trial NCT01686165?
The interventions under investigation include: rituximab (BIOLOGICAL), yttrium Y 90 ibritumomab tiuxetan (RADIATION), belinostat (DRUG).
Who is sponsoring clinical trial NCT01686165?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.